Interim Analysis in Cancer Clinical Trials
Author Information
Author(s): Irene Floriani, Nicole Rotmensz, Elena Albertazzi, Valter Torri, Marisa De Rosa, Carlo Tomino, Fillipo de Braud
Primary Institution: Istituto di Ricerche Farmacologiche 'Mario Negri'
Hypothesis
What are the current practices of interim analysis and data monitoring in cancer clinical trials?
Conclusion
There is still insufficient attention paid to the implementation of interim analysis in cancer clinical trials.
Supporting Evidence
- 70.7% of the protocols incorporate statistical interim analysis plans.
- Only 56% of protocols have a Data Safety Monitoring Committee (DSMC) and are considered adequately planned.
- 20% of the protocols lacked any form of monitoring.
- Most studies aimed to detect a difference in efficacy between treatment arms.
Takeaway
This study looked at how cancer trials check their results while they are still happening, and found that many don't do it well.
Methodology
The study analyzed protocols of cancer clinical trials from the Italian registry, focusing on randomised studies with time to event endpoints.
Potential Biases
Potential bias due to the reliance on protocol documentation which may lack detail.
Limitations
The study only included protocols from a specific registry and may not represent practices in other countries.
Participant Demographics
The majority of protocols were international and focused on solid tumors, particularly lung and breast cancers.
Statistical Information
Confidence Interval
95% CI 1.70–8.13
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website